PMID- 30596012
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231005
IS  - 2213-4220 (Print)
IS  - 2213-4239 (Electronic)
IS  - 2213-4220 (Linking)
VI  - 8
IP  - 1
DP  - 2019 Mar
TI  - Moxibustion for prehypertension and stage I hypertension: a pilot randomized 
      controlled trial.
PG  - 1-7
LID - 10.1016/j.imr.2018.11.002 [doi]
AB  - BACKGROUND: Prehypertension and hypertension are associated with cardiovascular 
      disease, ischemic heart disease, and stroke morbidity. The purpose of this study 
      is to evaluate the effectiveness and safety of moxibustion in patients with 
      prehypertension or hypertension. METHODS: Forty-five subjects with 
      prehypertension or stage I hypertension were randomized into three groups: 
      moxibustion treatment group A (2 sessions/week for 4 weeks), moxibustion 
      treatment group B (3 sessions/week for 4 weeks), and control group (nontreated 
      group). The primary outcome measure was the change in blood pressure after 4 
      weeks of treatment. Safety was assessed at every visit. RESULTS: There were no 
      significant differences in systolic blood pressure (SBP) or diastolic blood 
      pressure (DBP) among three groups after 4 weeks of treatment (p = 0.4798 and 
      p = 0.3252, respectively). In treatment group B, there was a significant decrease 
      in SBP and DBP from baseline to 4 weeks of treatment (mean difference (MD) -9.55; 
      p = 0.0225, MD -7.55; p = 0.0098, respectively). There were no significant 
      differences among groups in secondary outcome measures after 4 weeks of 
      treatment. Six adverse events (AEs) in the treatment group A and 12 AEs in the 
      treatment group B occurred related to the moxibustion treatment. CONCLUSION: In 
      conclusion, the results of this study show that moxibustion (3 sessions/week for 
      4 weeks) might lower blood pressure in patients with prehypertension or stage I 
      hypertension and treatment frequency might affect effectiveness of moxibustion in 
      BP regulation. Further randomized controlled trials with a large sample size on 
      prehypertension and hypertension should be conducted. TRIAL REGISTRATION: This 
      study was registered with the 'Clinical Research Information Service (CRIS)', 
      Republic of Korea (KCT0000469), and the protocol for this study was presented 
      orally at the 15th International Council of Medical Acupuncture and Related 
      Techniques (ICMART) in Athens, 25-27 May 2012.
FAU - Shin, Kyung-Min
AU  - Shin KM
AD  - Clinical Medicine Division, Korea Institute of Oriental Medicine, Daejeon, South 
      Korea.
FAU - Park, Ji-Eun
AU  - Park JE
AD  - Future Medicine Division, Korea Institute of Oriental Medicine, Daejeon, South 
      Korea.
FAU - Yook, Tae-Han
AU  - Yook TH
AD  - Department of Acupuncture & Moxibustion Medicine, Korean Medicine Hospital of 
      Woosuk University, Jeonju, South Korea.
FAU - Kim, Jong-Uk
AU  - Kim JU
AD  - Department of Acupuncture & Moxibustion Medicine, Korean Medicine Hospital of 
      Woosuk University, Jeonju, South Korea.
FAU - Kwon, Ojin
AU  - Kwon O
AD  - Clinical Medicine Division, Korea Institute of Oriental Medicine, Daejeon, South 
      Korea.
FAU - Choi, Sun-Mi
AU  - Choi SM
AD  - Korea Institute of Oriental Medicine, Daejeon, South Korea.
LA  - eng
PT  - Journal Article
DEP - 20181124
PL  - Netherlands
TA  - Integr Med Res
JT  - Integrative medicine research
JID - 101612707
PMC - PMC6309023
OTO - NOTNLM
OT  - AE, adverse event
OT  - BMI, body mass index
OT  - BP, blood pressure
OT  - CI, confidence interval
OT  - DBP, diastolic blood pressure
OT  - EQ-5D, EuroQol-5 Dimensions
OT  - FSS, Fatigue Severity Scale
OT  - HRV, heart rate variability
OT  - Hypertension
OT  - MD, mean difference
OT  - Moxibustion
OT  - NDI, neck disability index
OT  - PSQI, Pittsburgh Sleep Quality Index
OT  - Prehypertension
OT  - RCT, randomized controlled trial
OT  - SAE, serious adverse event
OT  - SBP, systolic blood pressure
OT  - SRI-MF, Modified Form of the Stress Response Inventory
EDAT- 2019/01/01 06:00
MHDA- 2019/01/01 06:01
PMCR- 2018/11/24
CRDT- 2019/01/01 06:00
PHST- 2018/08/28 00:00 [received]
PHST- 2018/11/06 00:00 [revised]
PHST- 2018/11/19 00:00 [accepted]
PHST- 2019/01/01 06:00 [entrez]
PHST- 2019/01/01 06:00 [pubmed]
PHST- 2019/01/01 06:01 [medline]
PHST- 2018/11/24 00:00 [pmc-release]
AID - S2213-4220(18)30258-0 [pii]
AID - 10.1016/j.imr.2018.11.002 [doi]
PST - ppublish
SO  - Integr Med Res. 2019 Mar;8(1):1-7. doi: 10.1016/j.imr.2018.11.002. Epub 2018 Nov 
      24.